Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(1):125–133. doi: 10.1111/j.1349-7006.2003.tb01363.x

Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status

Shin‐ichiro Masunaga 1,✉, Koji Ono 1, Akihisa Takahashi 3, Ken Ohnishi 3, Takeo Ohnishi 3, Minoru Suzuki 1, Kenji Nagata 1, Yuko Kinashi 2, Hideko Nagasawa 4, Yoshihiro Uto 4, Hitoshi Hori 4
PMCID: PMC11160248  PMID: 12708486

Abstract

Human head and neck squamous cell carcinoma cells transfected with mutant TP53 (SAS/mp53) or with neo vector as a control (SAS/neo) were inoculated subcutaneously into both hind legs of Balb/cA nude mice. Mice bearing the tumors received 5′‐bromo‐2′‐deoxyuridine (BrdU) continuously to label all proliferating (P) cells in the tumors. The mice then received tirapazamine (TPZ) with or without mild temperature hyperthermia (40°C, 60 min) (MTH), γ‐ray irradiation with or without MTH and/or TPZ, cisplatin (CDDP) with or without MTH and/or TPZ, or paclitaxel (TXL) with or without MTH and/or TPZ. After each treatment, the tumors were excised, minced and trypsinized. The tumor cell suspensions thus obtained were incubated with a cytokinesis blocker (cytochalasin‐B), and the micronucleus (MN) frequency in cells without BrdU labeling (i.e., quiescent (Q) cells) was determined by using immunofluorescence staining for BrdU. Meanwhile, 6 h after γ‐ray irradiation or 24 h after other cytotoxic treatments, tumor cell suspensions obtained in the same manner were used for determining the frequency of apoptosis in Q cells. The MN frequency and apoptosis frequency in total (P+Q) tumor cells were determined from the tumors that were not pretreated with BrdU. On the whole, γ‐ray irradiation and CDDP injection induced a higher frequency of apoptosis and lower frequency of MN in SAS/neo cells than SAS/mp53 cells. There were no apparent differences in the induced frequency of apoptosis and MN between SAS/neo and SAS/mp53 cells after TPZ or TXL treatment. MTH sensitized cells to TPZ‐inducing cytotoxicity more markedly in SAS/mp53 and Q cells than in SAS/neo cells and total cells, respectively. In y‐ray irradiation and CDDP treatment, the enhancement in combination with MTH and/or TPZ was more remarkable in SAS/mp53 cells and Q cells than in SAS/neo and total tumor cells, respectively. Also in the case of TXL treatment, the combination with MTH and/or TPZ induced a slightly greater enhancement effect in SAS/mp53 cells and Q cells. In view of the difficulty in controlling mutated p53 status tumors and intratumor Q cells, combination treatment with MTH and/or TPZ as a cooperative modality in cancer therapy is considered to have potential for controlling solid tumors as a whole. (Cancer Sci 2003; 94: 125–133)

References

  • 1. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/ M and the cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995; 92: 8493–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Mummenbrauer T, Janus F, Muller B, Wiesmuller L, Deppert W, Grosse F. p53 protein exhibits 3'‐to‐5′ exonuclease activity. Cell 1996; 85: 1089–99. [DOI] [PubMed] [Google Scholar]
  • 3. Caelles C, Helmberg A, Karin M. p53‐dependent apoptosis in the absence of transcriptional activation of p53‐target genes. Nature 1994; 370: 220–3. [DOI] [PubMed] [Google Scholar]
  • 4. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 435–56. [DOI] [PubMed] [Google Scholar]
  • 5. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995; 7: 547–53. [DOI] [PubMed] [Google Scholar]
  • 6. Griffin RJ, Okajima K, Ogawa A, Song CW. Radiosensitization of two murine tumours with mild temperature hyperthermia and carbogen breathing. Int J Radiat Biol 1999; 75: 1299–306. [DOI] [PubMed] [Google Scholar]
  • 7. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408–16. [PubMed] [Google Scholar]
  • 8. Masunaga S, Ono K, Akaboshi M, Kawai K, Suzuki M, Kinashi Y, Takagaki M. Augumentation in chemosensitivity of intratumor quiescent cells by combined treatment with nicotinamide and mild hyperthermia. Jpn J Cancer Res 1997; 88: 770–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Masunaga S, Ono K. Significance of the response of quiescent cell populations within solid tumors in cancer therapy. J Radiat Res 2002; 43: 11–25. [DOI] [PubMed] [Google Scholar]
  • 10. Masunaga S, Ono K, Takahashi A, Ohnishi T, Kinashi Y, Takagaki M. Ra‐diobiological characteristics of solid tumours depending on the p53 status of the tumour cells, with emphasis on the response of intratumour quiescent cells. Eur J Cancer 2002; 38: 718–27. [DOI] [PubMed] [Google Scholar]
  • 11. Takahashi A. Different inducibility of radiation‐ or heat‐induced p53‐depen‐dent apoptosis after acute or chronic irradiation in human cultured squamous cell carcinoma cells. Int J Radiat Biol 2001; 77: 215–24. [DOI] [PubMed] [Google Scholar]
  • 12. Ohnishi K, Wang X, Takahashi A, Ohnishi T. Contribution of protein kinase C to p53 dependent WAF1 induction pathway after heat treatment in human glioblastoma cell lines. Exp Cell Res 1998; 238: 399–406. [DOI] [PubMed] [Google Scholar]
  • 13. Masunaga S, Ono K, Hori H, Kinashi Y, Suzuki M, Takagaki M, Kasai S, Nagasawa H, Uto Y. Modification of tirapazamine‐induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells. Int J Hyperthermia 1999; 15: 7–16. [DOI] [PubMed] [Google Scholar]
  • 14. Milross CG, Mason KA, Hunter NR, Terry NHA, Patel N, Harada S, Jibu T, Seong J, Milas L. Enhanced radioresponse of paclitaxel‐sensitive and ‐resistant tumours in vivo . Eur J Cancer 1997; 33: 1299–308. [DOI] [PubMed] [Google Scholar]
  • 15. Dorie MJ, Brown JM. Tumor‐specific, schedule dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993; 53: 4633–6. [PubMed] [Google Scholar]
  • 16. Stephens LC, Ang KK, Schultheiss TE, Milas L, Meyn RE. Apoptosis in irradiated murine tumors. Radiat Res 1991; 127: 308–16. [PubMed] [Google Scholar]
  • 17. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–62. [DOI] [PubMed] [Google Scholar]
  • 18. Seng F, Ley K. Simple synthesis of 3‐amino‐1,2,4‐benzotriazine‐1,4‐diox‐ide. Angew Chem Int Ed Engl 1972; 11: 1009–10. [Google Scholar]
  • 19. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR‐4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986; 12: 1239–42. [DOI] [PubMed] [Google Scholar]
  • 20. Nishimura Y, Ono K, Hiraoaka M, Masunaga S, Jo S, Shibamoto Y, Sasai K, Abe M, Iga K, Ogawa Y. Treatment of murine SCCVII tumors with localized hyperthermia and temperature‐sensitive liposomes containing cisplatin. Radiat Res 1990; 122: 161–7. [PubMed] [Google Scholar]
  • 21. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990; 50: 7745–9. [PubMed] [Google Scholar]
  • 22. Dorie MJ, Brown JM. Modification of the antitumor activity of chemothera‐peutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 1997; 39: 361–6. [DOI] [PubMed] [Google Scholar]
  • 23. Ota I, Ohnishi K, Takahashi A, Yane K, Kanata H, Miyahara H, Ohnishi T, Hosoi H. Transfection with mutant p53 gene inhibits heat‐induced apoptosis in a head and neck cell line of human squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000; 47: 495–501. [DOI] [PubMed] [Google Scholar]
  • 24. Meyn RE, Stephens LC, Ang KK, Hunter NR, Brock WA, Milas L, Peters LJ. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol 1993; 64: 583–91. [DOI] [PubMed] [Google Scholar]
  • 25. Guo GZ, Sasai K, Oya N, Takagi T, Shibuya K, Hiraoka M. Simultaneous evaluation of radiation‐induced apoptosis and micronuclei in five cell lines. Int J Radiat Biol 1998; 73: 297–302. [DOI] [PubMed] [Google Scholar]
  • 26. Masunaga S, Ono K, Abe M. The detection and modification of the hypoxic fraction in quiescent cell populations in murine solid tumors. Br J Radiot 1993; 66: 918–26. [DOI] [PubMed] [Google Scholar]
  • 27. Masunaga S, Ono K, Suzuki M, Kinashi Y, Takagaki M, Akaboshi M. Alteration of the hypoxic fraction of quiescent cell populations by hyperthermia at mild temperatures. Int J Hyperthermia 1997; 13: 401–11. [DOI] [PubMed] [Google Scholar]
  • 28. Masunaga S, Ono K, Akaboshi M, Nishimura Y, Suzuki M, Kinashi Y, Takagaki M, Hiraoka M, Abe M. Reduction of hypoxic cells in solid tumours induced by mild hyperthermia: special reference to differences in changes in the hypoxic fraction between total and quiescent cell populations. Br J Cancer 1997; 76: 588–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Masunaga S, Ono K, Suzuki M, Kinashi Y, Takagaki M, Hori H, Kasai S, Nagasawa H, Uto Y. Usefulness of tirapazamine as a combined agent in chemoradiation and thermo‐chemoradiation therapy at mild temperatures: reference to the effect on intratumor quiescent cells. Jpn J Cancer Res 2000; 91: 566–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Masunaga S, Ono K, Hori H, Akaboshi M, Kawai K, Kinashi Y, Suzuki M. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low temperature hyperthermia. Radiat Med 1998; 16: 441–8. [PubMed] [Google Scholar]
  • 31. Masunaga S, Ono K, Suzuki M, Nishimura Y, Kinashi Y, Takagaki M, Hori H, Nagasawa H, Uto Y, Tsuchida I, Sadahiro S, Murayama C. Radiosensiti‐zation effect by combination with paclitaxel in vivo, including the effect on intratumor quiescent cells. Int J Radiat Oncol Biol Phys 2001; 50: 1063–72. [DOI] [PubMed] [Google Scholar]
  • 32. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788–93. [PubMed] [Google Scholar]
  • 33. Roth JA, Swisher SG, Mevn RE. p53 tumor suppressor gene therapy for cancer. Oncology (Huntingt) 1999; 13: 148–54. [PubMed] [Google Scholar]
  • 34. Jabbur JR, Huang P, Zhang W. DNA damage‐induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm‐2 induction in vivo . Oncogene 2000; 19: 6203–8. [DOI] [PubMed] [Google Scholar]
  • 35. Kearsey JM, Shivji MK, Hall PA, Wood RD. Does the p53 up‐regulated Gadd45 protein have a role in excision repair? Science 1995; 270: 1004–5. [discussion] 1005–6. [PubMed] [Google Scholar]
  • 36. Smith MI, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ Jr. Interaction of the p53‐regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266: 1376–80. [DOI] [PubMed] [Google Scholar]
  • 37. Szumiel I. Ionizing radiation‐induced cell death. Int J Radiat Biol 1994; 66: 329–41. [DOI] [PubMed] [Google Scholar]
  • 38. Lowe SW, Ruley HE, Lacks T, Housman DE. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–67. [DOI] [PubMed] [Google Scholar]
  • 39. Tan G, Heqing L, Jiangbo C, Ming J, Yanhong M, Xianqhe L, Hong S, Li G. Apoptosis induced by low‐dose paclitaxel is associated with p53 upregula‐tion in nasopharyngeal carcinoma cells. Int J Cancer 2002; 97: 168–72. [DOI] [PubMed] [Google Scholar]
  • 40. Gandara DR, Lara PN, Goldberg Z, Le QT, Mack PC, Lou DH, Gumerlock PH. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 2002; 29 (1 Suppl 4): 102–9. [DOI] [PubMed] [Google Scholar]
  • 41. Kanata H, Yane K, Ota I, Miyahara H, Matsunaga T, Takahashi A, Ohnishi K, Ohnishi T, Hosoi H. CDDP induced p53‐dependent apoptosis in tongue cancer cells. Int J Oncol 2000; 17: 513–7. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES